Pharmaceutical corporation ViiV must improve its failing access strategy for lifesaving HIV prevention drug

With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries